Identification of bromodeoxyuridine in malignant and normal cells following therapy: relationship to complications.
During a clinical Phase I study of bromodeoxyuridine (BUdR) as a radiation sensitizer we identified the normal and malignant cells that incorporated the BUdR. BUdR was infused for up to 14 days and the in vivo incorporation of BUdR into DNA was assessed using an immunohistochemical technique and a monoclonal antibody directed against BUdR. BUdR was identified in 50% of breast cancer cells and 10% of cells in a malignant melanoma. BUdR was also found in the basal layer of the normal epidermis and in 50% of cells in the marrow. The incorporation of BUdR into cells in the epidermis and marrow may produce the phototoxicity and myelosuppression observed in patients treated with BUdR. Sequential biopsies from a breast cancer taken prior to and following radiotherapy suggested that cells that incorporated BUdR may have been selectively killed by the radiation. The immunohistochemical technique used to identify BUdR appeared to be useful for studies of in vivo and in vitro cell proliferation.
D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D001973:Bromodeoxyuridine / Q000009:adverse effects / Q000378:metabolism*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D009369:Neoplasms / Q000378:metabolism*; D010787:Photosensitivity Disorders / Q000139:chemically induced; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000378:metabolism*; D012867:Skin / Q000187:drug effects
D011838:Radiation-Sensitizing Agents; D001973:Bromodeoxyuridine